Armata Short Long Term Debt Total from 2010 to 2025

ARMP Stock  USD 2.08  0.09  4.15%   
Armata Pharmaceuticals Short and Long Term Debt Total yearly trend continues to be relatively stable with very little volatility. Short and Long Term Debt Total is likely to grow to about 145.3 M this year. During the period from 2010 to 2025, Armata Pharmaceuticals Short and Long Term Debt Total destribution of quarterly values had range of 144.5 M from its regression line and mean deviation of  40,921,492. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
1993-12-31
Previous Quarter
146.1 M
Current Value
140.3 M
Quarterly Volatility
32.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 3.2 M or Selling General Administrative of 10 M, as well as many indicators such as Price To Sales Ratio of 28.2, Dividend Yield of 0.0175 or Days Sales Outstanding of 256. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Armata Pharmaceuticals Correlation against competitors.
To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Latest Armata Pharmaceuticals' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Armata Pharmaceuticals over the last few years. It is Armata Pharmaceuticals' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Armata Short Long Term Debt Total Regression Statistics

Arithmetic Mean32,715,540
Geometric Mean6,339,804
Coefficient Of Variation161.16
Mean Deviation40,921,492
Median2,863,000
Standard Deviation52,725,987
Sample Variance2780T
Range144.5M
R-Value0.79
Mean Square Error1106.1T
R-Squared0.63
Significance0.0002
Slope8,780,800
Total Sum of Squares41700.4T

Armata Short Long Term Debt Total History

2025145.3 M
2024138.4 M
2023120.4 M
202248.8 M
202138 M
202013.2 M

About Armata Pharmaceuticals Financial Statements

Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Short and Long Term Debt Total138.4 M145.3 M

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.